These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
412 related articles for article (PubMed ID: 18471155)
1. Developments in the epidemiolgy of invasive fungal infections - implications for the empiric and targeted antifungal therapy. Hof H Mycoses; 2008; 51 Suppl 1():1-6. PubMed ID: 18471155 [TBL] [Abstract][Full Text] [Related]
2. Candida and candidaemia. Susceptibility and epidemiology. Arendrup MC Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246 [TBL] [Abstract][Full Text] [Related]
3. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance. Fera MT; La Camera E; De Sarro A Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707 [TBL] [Abstract][Full Text] [Related]
4. Caspofungin: a major breakthrough in treatment of systemic fungal infections. Agarwal MB; Rathi SA; Ratho N; Subramanian R J Assoc Physicians India; 2006 Dec; 54():943-8. PubMed ID: 17334012 [TBL] [Abstract][Full Text] [Related]
5. New antifungal agents. Gupta AK; Tomas E Dermatol Clin; 2003 Jul; 21(3):565-76. PubMed ID: 12956208 [TBL] [Abstract][Full Text] [Related]
6. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values. Pfaller MA; Rhomberg PR; Messer SA; Jones RN; Castanheira M Diagn Microbiol Infect Dis; 2015 Aug; 82(4):303-13. PubMed ID: 25986029 [TBL] [Abstract][Full Text] [Related]
8. Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections. Castanheira M; Messer SA; Jones RN; Farrell DJ; Pfaller MA Int J Antimicrob Agents; 2014 Oct; 44(4):320-6. PubMed ID: 25129315 [TBL] [Abstract][Full Text] [Related]
9. The echinocandins. Cappelletty D; Eiselstein-McKitrick K Pharmacotherapy; 2007 Mar; 27(3):369-88. PubMed ID: 17316149 [TBL] [Abstract][Full Text] [Related]
10. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance. Xiao M; Fan X; Chen SC; Wang H; Sun ZY; Liao K; Chen SL; Yan Y; Kang M; Hu ZD; Chu YZ; Hu TS; Ni YX; Zou GL; Kong F; Xu YC J Antimicrob Chemother; 2015 Mar; 70(3):802-10. PubMed ID: 25473027 [TBL] [Abstract][Full Text] [Related]
11. Echinocandins: the newest class of antifungals. Sucher AJ; Chahine EB; Balcer HE Ann Pharmacother; 2009 Oct; 43(10):1647-57. PubMed ID: 19724014 [TBL] [Abstract][Full Text] [Related]
12. [Drugs used in prophylaxis and treatment of fungal infections in immunosuppressed children]. Balwierz W Przegl Lek; 2004; 61 Suppl 2():89-94. PubMed ID: 15686055 [TBL] [Abstract][Full Text] [Related]
18. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009). Pfaller MA; Messer SA; Moet GJ; Jones RN; Castanheira M Int J Antimicrob Agents; 2011 Jul; 38(1):65-9. PubMed ID: 21514797 [TBL] [Abstract][Full Text] [Related]